Syeda Kit
Product Images NDC 70700-115

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Syeda (NDC 70700-115). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed, Llc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Syeda Blister

Syeda drospirenone and ethinyl estradiol tablets kit packaging label showing a calendar layout for a 28-day cycle with weekly rows and daily dose circles labeled from Sunday to Saturday. The label includes the product name, active ingredients, strength 3 mg/0.03 mg, and a visual guide for daily tablet intake.*

FDA Label Image

Syeda-carton (Syeda Carton)

Label for Syeda kit by Xiromed, LLC containing Drospirenone and Ethinyl Estradiol tablets, USP 3 mg/0.03 mg. The package includes 3 units, each with a 28-day regimen in 3x28 tablet blistercards. The label features orange and light green design elements and states prescription use (Rx only).*

FDA Label Image

Syeda Chemical Structure

Chemical structures of the active ingredients Drospirenone and Ethinyl estradiol, shown with their molecular configurations labeled clearly below each structure.*

FDA Label Image

Syeda Figure 1

A forest plot titled 'VTE Risk with Drospirenone and Ethinyl Estradiol Relative to LNG-Containing COCs (adjusted risk)' comparing various studies including Ingenix, EURAS, LASS, FDA-funded, Danish, MEGA, German case-control, PharMetrics, and GPRD. The graph shows hazard ratios, rate ratios, and odds ratios with confidence intervals for venous thromboembolism risk, grouped by study type: prospective cohort, retrospective cohort, case-control, and non-fatal idiopathic cases only.*

FDA Label Image

Syeda Figure 2

A horizontal bar graph titled 'Likelihood of Developing a VTE' comparing the number of women with blood clots per 10,000 women years for different groups: Non-Pregnant Non-COC users, COC users, Pregnancy, and Postpartum (12 weeks only). Each group shows ranges of incidence, with postpartum having the highest range from 40 to 65 cases, followed by pregnancy (5 to 20), COC users (3 to 9), and non-pregnant non-COC users (1 to 5). Additional notes clarify pregnancy duration assumptions.*

FDA Label Image

Syeda Figure 3

A forest plot depicting effect estimates from various cohort studies comparing Ever COC use versus Never COC use and Current COC use versus Never-Use. The horizontal axis represents the effect estimate ranging from -1.50 to 2.00. Data points with confidence intervals are shown for studies including NICHD Women's Care Study, French ESN cohort, Shanghai Women's Health Study, The Nurses' Health Study II, Oxford Family Planning Study, and Danish Sex Hormone Register Study.*

FDA Label Image

Syeda Figure 4

An illustration showing the relative effectiveness of various birth control methods, with a vertical arrow indicating fewer pregnancies at the top and more pregnancies at the bottom. Methods listed from most to least effective include implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring with hormones, condoms, diaphragm, no sex during fertile days, spermicide, withdrawal, and no birth control at the bottom.*

FDA Label Image

Syeda Figure 5

A horizontal bar chart illustrating the likelihood of developing a serious blood clot in different groups of women per 10,000 women years (WY). Groups include Non-Pregnant Non-COC users (1 to 5 cases), COC-Users (3 to 9 cases), Pregnancy (5 to 20 cases), and Postpartum (12 weeks only) (40 to 65 cases). The x-axis shows the number of women with blood clots, ranging from 0 to 70.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.